Biogen Hikes Guidance On Solid Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
More MS patients now outside the U.S. than inside, company says.
You may also be interested in...
Tysabri Continues Comeback; On Pace To Reach 100,000 Patients In 2010
The once-withdrawn MS drug continues to gain patients in the U.S. and EU, with an improving safety profile, Biogen says.
Tysabri Continues Comeback; On Pace To Reach 100,000 Patients In 2010
The once-withdrawn MS drug continues to gain patients in the U.S. and EU, with an improving safety profile, Biogen says.
Rituxan For Lupus Misses Primary, Secondary Endpoints
Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.